share_log

君实生物自愿披露关于特瑞普利单抗联合贝伐珠单抗一线治疗晚期肝细胞癌的III期临床研究达到主要研究终点的公告

Junshi Bio has voluntarily disclosed an announcement regarding the phase III clinical study of the combination of Teriprizumab and Bevacizumab as first-line treatment for advanced hepatocellular carcinoma reaching the primary endpoint.

SZSI ·  Jun 11
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more